Abstract
612P Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have